Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Masoud Sultani

Anesthesiology Phoenix, AZ Medical Doctor

NPI 1104237478 CMS profile 5700506

5501 N 19Th Ave Ste 103, Phoenix, AZ 85015

Open in the dashboard

General payments

$10,881

14 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Masoud Sultani of Phoenix, AZ is reported in the CMS Open Payments database as having received $10,881 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $129 1
2024 General $167 2
2022 General $65 3
2021 General $269 2
2020 General $237 3
2019 General $10,014 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Masoud Sultani
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Masoud Sultani were reported at $129. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Masoud Sultani Anesthesiology median Middle half National median
2019 $10,014 $72 $23–$151 $163
2020 $237 $36 $17–$120 $114
2021 $269 $49 $21–$135 $132
2022 $65 $52 $22–$144 $149
2023 $0 $53 $23–$143 $160
2024 $167 $55 $25–$150 $164
2025 $129 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $10,000 2 payments
  2. Abbott Laboratories $351 4 payments
  3. Boston Scientific Corporation $245 3 payments
  4. Stryker Corporation $129 1 payment
  5. SPR Therapeutics, Inc $86 1 payment
  6. Medtronic, Inc. $28 1 payment
  7. Nalu Medical, Inc. $25 1 payment
  8. Dendreon Pharmaceuticals LLC $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $10,000 2 payments
  2. Food and Beverage $881 12 payments
Products named General payments · program years 2019–2025
  1. SYNCHROMED $10,000 2 payments
  2. Proclaim IPG $172 1 payment
  3. ETERNA $143 1 payment
  4. SPECTRA WAVEWRITER $133 1 payment
  5. MILD DEVICE KIT $129 1 payment
  6. Superion $98 1 payment
  7. SPRINT PNS System $86 1 payment
  8. PROCLAIM $37 2 payments
  9. EndoFlip $28 1 payment
  10. Nalu Neurostimulation System $25 1 payment
  11. Other $31 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

972

Median for Anesthesiology: 322

Drug cost

$15,106

Median for Anesthesiology: $8,738

Branded share of claims

31.1%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 128 $3,005
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 138 $2,354
Gabapentin Generic 110 $1,691
Tizanidine Hcl Generic 158 $1,611
Morphine Sulfate Er Morphine Sulfate Brand 36 $923
Oxycodone Hcl Generic 65 $825
Diclofenac Sodium Generic 25 $674
Naloxone Hcl Generic 11 $620
Pregabalin Generic 48 $617
Methocarbamol Generic 17 $574

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$113,257

Of which drugs: $128

Medicare patients

350

Average age 76

Services billed

1,598

205 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 33%
Diabetes 31%
Chronic kidney disease 30%
Depression 29%
Atrial fibrillation 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 169 $127

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record